Pricing Log in Create free account
Friday 6 November 2026 Export KRMD’s income statement to Excel — free account

KORU Medical Systems, Inc.

KRMD Healthcare Medical Instruments & Supplies

KORU Medical Systems, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $41.1 million, up 22.2% from fiscal 2024.

Revenue
+18.2%
EPS
+222.2%
Free cash flow
+26.2%
Total debt
−50.9%

Quarter to June 2026, against a year earlier

3.02 0.25 −7.65%
Market cap
$139.9M
P/E
0.0×
Fwd P/E
−74.8×
Dividend yield
—
F-score
5/9
Altman Z
14.46
Beneish M
−2.90
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 0.22
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — 4 1 — — 1 — —
Sell — — — — — — — — — — — —
Insider Ownership 6.58%

Capital & Financial Ratios $m

Size
Market Cap 139.90
Revenue ttm 45.11
Net income ttm (1.82)
Free cash flow ttm 0.25
Net debt Q (8.22)
Valuation
P/E 0.00
Forward P/E (74.80) (negative: loss-making)
Price / sales 3.09
Forward P/S Powerpack
Price / FCF 557.36
Price / book 7.71 (above 6: high)
Financial health
Current ratio Q 2.72 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (13.23)
Growth
Revenue growth Q +18.15% (above 0%: growing)
Operating income growth Q +300.51% (above 0%: growing)
EPS, this year +34.88% (at or above 15%: strong)
EPS, next year A +152.85% (at or above 15%: strong)
Revenue, next year A +16.78% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A +41.57% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.9×, against a ten-year median of 3.8×; over the ten years it ranged from 0.7× in 2016 to 19.2× in 2020.
P/S against its own 10 years 20.50%
10-year low 10-year high
P/B against its own 10 years 71.69%
10-year low 10-year high
EV/Sales against its own 10 years 22.19%
10-year low 10-year high
EV/FCF against its own 10 years 76.25%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 11 10 9 8
Receivables 4 6 7 6
Inventory 3 3 4 5
Other — — — —
20 19 20 20
2023 2024 2025 Q'26
Payables 1 2 2 3
ST’ Debt — — — —
Other 1 0 0 0
4 7 8 7

Compound Annual Growth %

10y 5y 3y
Sales 12.88% 11.21% 13.81%
Cash Flow (13.25%) 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 9.13% (13.96%) (18.36%)

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.02 Actual 0.01

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 −0.03 −0.02 Beat by 0.01
Q4 FY25 −0.02 −0.01 Beat by 0.01
Q1 FY26 −0.02 −0.02 Met by 0.00
Q2 FY26 −0.02 0.01 Beat by 0.03
Q3 FY26 0.00 — Reports 10 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (0.02) 0.01 — — —
’25 (0.03) 0.00 (0.02) (0.01) (0.06)
’24 (0.04) (0.02) (0.03) (0.03) (0.13)
’23 (0.05) (0.05) (0.03) (0.16) (0.30)
’22 (0.06) (0.07) (0.03) (0.04) (0.19)
’21 (0.03) (0.03) (0.02) (0.02) (0.10)
’20 0.01 (0.03) 0.01 (0.02) (0.03)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 12 12 — — —
’25 10 10 10 11 41
’24 8 8 8 9 34
’23 7 7 7 7 29
’22 6 7 8 7 28
’21 5 6 6 6 23
’20 6 8 6 4 24
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 0 0 — — —
’25 0 0 0 1 0
’24 0 0 (1) 1 0
’23 (5) 0 (1) 1 (5)
’22 (2) (3) (2) 1 (5)
’21 (3) 0 (1) (1) (4)
’20 0 3 (2) (2) (1)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 0 0 — — —
’25 (1) 0 0 1 0
’24 0 0 (2) 1 (2)
’23 (5) 0 (1) 1 (6)
’22 (3) (4) (3) 1 (8)
’21 (3) 0 (1) (1) (5)
’20 0 2 (2) (2) (2)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.5
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 12 13 17 23 24 23 28 29 34 41 45 +14.4% 48 56 65 +16.4%
Gross margin, % 59.86 61.13 62.30 64.13 61.78 58.62 55.09 58.59 63.40 62.26 62.43 +2.4 pt
EBT 1 1 1 1 (1) (6) (11) (10) (6) (3) (2) n/m
EBT margin, % 9.33 9.82 6.78 3.01 (4.94) (27.09) (38.27) (34.27) (18.02) (6.36) (4.01) (15.7) pt
Net income 1 1 1 1 (1) (5) (9) (14) (6) (3) (2) n/m
Per share, $
Per share, $ Revenue 0.32 0.35 0.46 0.60 0.58 0.53 0.62 0.63 0.73 0.89 0.98 +12.0%
Earnings 0.02 0.02 0.02 0.01 (0.03) (0.10) (0.19) (0.30) (0.13) (0.06) (0.04) n/m
Cash flow 0.05 0.02 0.04 0.01 (0.02) (0.10) (0.12) (0.11) (0.01) 0.01 0.03 (16.4%)
Capex 0.00 (0.01) (0.01) (0.01) (0.02) (0.01) (0.06) (0.02) (0.03) (0.02) (0.02) n/m
Free cash flow 0.05 0.02 0.03 0.00 (0.04) (0.11) (0.18) (0.13) (0.04) (0.01) 0.01 n/m
Book value 0.19 0.20 0.24 0.29 0.86 0.82 0.70 0.45 0.37 0.37 0.39 +7.8%
Shares, m 38 38 38 39 42 44 45 46 46 46 46 +2.2%
Valuation, ×
Valuation, × P/E 0.00 44.35 77.46 366.85 0.00 0.00 0.00 0.00 0.00 0.00 0.00 48.9
P/S 1.37 3.02 3.63 10.93 10.44 5.67 5.73 3.81 5.24 6.52 3.09 5.6
P/B 2.52 5.24 7.02 22.54 6.98 3.65 5.10 5.33 10.49 15.74 7.71 8.5
EV/Sales 1.08 2.70 3.32 10.68 9.31 4.59 5.12 3.41 4.96 6.31 2.90 5.1
EV/FCF (12.88) 52.72 57.39 2,192.84 (126.56) (23.02) (17.39) (17.06) (101.02) (532.53) 524.46 147.2
Cash, $m
Cash, $m Operating cash flow 2 1 1 0 (1) (4) (5) (5) 0 0 1 (14.6%)
Capex 0 0 0 0 (1) 0 (3) (1) (1) (1) (1) +18.8%
Free cash flow 2 1 1 0 (2) (5) (8) (6) (2) 0 0 n/m
Balance, $m
Balance, $m Working capital 6 6 7 9 34 33 23 16 12 12 12 +7.8%
Net debt (4) (4) (5) (6) (27) (25) (17) (11) (9) (9) (8) +7.8%
Shareholders’ equity 7 8 9 11 36 37 31 20 17 17 18 +10.2%
Returns, %
Returns, % ROA 9.33 10.37 9.19 4.62 (4.51) (11.24) (20.71) (38.82) (21.79) (9.52) (6.81) (18.8) pt
ROIC 0.00 22.52 19.65 6.82 (8.78) (39.35) (47.08) (69.86) (54.19) (22.51) (10.50) (22.5) pt
ROE 11.00 12.62 10.95 5.59 (5.12) (12.56) (25.54) (53.18) (32.64) (15.58) (10.52) (26.6) pt
People
People Employees 55 69 76 71 101 77 86 82 80 73 — +3.2%
Revenue/emp, $m 0.00 0.00 0.23 0.33 0.24 0.31 0.32 0.35 0.42 0.56 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 2 Nov 2026

KORU Medical Systems, Inc. vs peers in Medical Instruments & Supplies (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
EMBC Embecta Corp. $358.7M 4.2× 5.3× −8.05% (below 0%: shrinking) −53.85% (below 0%: shrinking) −49.63% (below 0%: shrinking) 56.42% 17.92% Compare
SMTI Sanara MedTech Inc. $290.4M — (loss-making) 164× +9.04% (above 0%: growing) n/m +131.28% (above 0%: growing) 92.96% 6.33% Compare
OSUR OraSure Technologies, Inc. $232.4M — (loss-making) — (loss-making) −1.93% (below 0%: shrinking) n/m −1.40% (below 0%: shrinking) 43.46% 17.76% Compare
UTMD Utah Medical Products, Inc. $202.4M 21.7× 28.7× −14.31% (below 0%: shrinking) −10.64% (below 0%: shrinking) −55.74% (below 0%: shrinking) 55.79% 31.06% Compare
PDEX Pro-Dex, Inc. $195.8M 16.4× 18.8× +10.96% (above 0%: growing) −33.57% (below 0%: shrinking) +177.76% (above 0%: growing) 33.35% 17.10% Compare
KRMD KORU Medical Systems, Inc. $139.9M — (loss-making) — (loss-making) +18.15% (above 0%: growing) n/m +26.17% (above 0%: growing) 65.14% 5.21%
STXS Stereotaxis Inc. $105.2M — (loss-making) — (loss-making) −12.82% (below 0%: shrinking) n/m +0.45% (above 0%: growing) 58.49% (59.56%) Compare
ZTEKF Zentek Ltd. $62.3M — (loss-making) — −95.36% (below 0%: shrinking) n/m −254.61% (below 0%: shrinking) 0.00% 0.00% Compare
POCI Precision Optics Corp. $54.3M — (loss-making) — (loss-making) +41.95% (above 0%: growing) n/m −45.64% (below 0%: shrinking) 25.34% (1.21%) Compare
Median of peers $199.1M 16.4× 23.8× −4.99% −33.57% −23.52% 49.62% 11.72%

All 53 Medical Instruments & Supplies stocks →

Pay and ownership Proxy statement filed 9 April 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 1.74m 3.25m 162.75
2024 1.27m 1.93m 107.84
2023 713.37k (1.19m) 68.77

Ownership

Directors and executive officers, together 18.50%
Joseph M. Manko, Jr. 12.60%
Horton Capital Management, LLC 12.60%
Topline Capital Management, LLC 8.50%
First Light Asset Management, LLC 8.20%
BlackRock, Inc. 5.00%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

KORU Medical Systems, Inc. (KRMD) Latest News

12 Aug

Impact 3 · · The Motley Fool transcript

6 Aug

Impact 4 · transcript

5 Aug

Impact 3 · · MarketBeat
Impact 3 · · Moby transcript
Impact 3 ·
Impact 3 ·

7 May

Impact 3 · · Moby

6 May

Impact 4 · · MarketBeat
Impact 4 · · Business Wire

1 May

Impact 3 · · Simply Wall St.

17 Mar

Impact 4 · · Zacks

13 Mar

Impact 4 · · Moby
Impact 4 · · Business Wire

12 Mar

Impact 4 · · GuruFocus.com
Impact 4 · · MarketBeat
Impact 4 · · Business Wire
Impact 4 · · Business Wire
Impact 3 · · Zacks

12 Feb

Impact 3 · · Zacks

10 Feb

Impact 3 · · Simply Wall St.
Impact 3 · · Simply Wall St.

9 Feb

Impact 4 · · Simply Wall St.

6 Feb

Impact 3 · · Simply Wall St.
Impact 3 · · Simply Wall St.

3 Feb

Impact 3 ·

30 Jan

Impact 4 · · medicaldevice-network.com

29 Jan

Impact 4 · · Business Wire

21 Jan

Impact 4 · · Zacks

12 Jan

Impact 4 · · Business Wire

9 Jan

Impact 4 · · ZacksZacksZacksZacksMotley FoolZacksZacksBarchart
stockrow.com/KRMD · Data as of Nov 2, 2026 · For information only; not investment advice. · © 2026 stockrow.com